Selected article for: "acute kidney failure and respiratory distress syndrome"
Author: Roberts, Lara N.; Bramham, Kate; Sharpe, Claire C.; Arya, Roopen
Title: Hypercoagulability and anticoagulation in patients with COVID-19 requiring renal replacement therapy
  • Cord-id: 3hvedj2c
  • Document date: 2020_7_25
    • ID: 3hvedj2c
    Snippet: Severe acute respiratory coronavirus 2 (SARS-CoV2) and the resulting acute respiratory distress syndrome (COVID-19) is responsible for a worldwide pandemic, with over 10 million cases reported as of 28(th) June 2020.(S1) Whilst severe disease requiring hospitalisation is characterised by pneumonia and respiratory failure, a significant proportion also develop acute kidney injury (AKI). Within critical care admissions with COVID-19, 16 to 35% are reported as requiring renal replacement therapy.(2
    Document: Severe acute respiratory coronavirus 2 (SARS-CoV2) and the resulting acute respiratory distress syndrome (COVID-19) is responsible for a worldwide pandemic, with over 10 million cases reported as of 28(th) June 2020.(S1) Whilst severe disease requiring hospitalisation is characterised by pneumonia and respiratory failure, a significant proportion also develop acute kidney injury (AKI). Within critical care admissions with COVID-19, 16 to 35% are reported as requiring renal replacement therapy.(2)(,)(3)(, S2,S3) There is increasing recognition of an associated coagulopathy in hospitalised patients characterised by a prothrombotic state and increased venous thromboembolism. This brief review presents the current understanding of the coagulopathy associated with COVID-19, the risk of venous thrombosis and the impact of this on management of renal replacement therapy in critically ill patients with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • active bleeding and acute kidney injury: 1, 2
    • active bleeding and acute respiratory distress syndrome: 1, 2
    • active bleeding and lmwh weight heparin: 1, 2
    • active bleeding and low molecular lmwh weight heparin: 1, 2
    • acute aki kidney injury and lmwh weight heparin: 1, 2
    • acute aki kidney injury and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute aki kidney injury and low molecular lmwh weight heparin: 1, 2
    • acute kidney injury and lmwh weight heparin: 1, 2, 3
    • acute kidney injury and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute kidney injury and low molecular lmwh weight heparin: 1, 2, 3
    • acute kidney injury and machine patient: 1, 2
    • acute respiratory distress syndrome and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory distress syndrome and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory distress syndrome and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory distress syndrome and machine patient: 1
    • adhesion follow and low incidence: 1
    • lmwh weight heparin and low incidence: 1, 2, 3, 4, 5
    • lmwh weight heparin and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25